Berhyanda gets DoP nod to acquire up to 76.1 percent stake in Suven Pharma
Hyderabad: Through a recent BSE filing, Suven Pharma has informed that the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has granted its approval for acquisition of up to 76.1% shareholding in the Company by M/s. Berhyanda Limited, Cyprus (“Acquirer”) by way of transfer of 12,75,37,043 equity shares aggregating to 50.1% of shareholding in the Company from promoters of the Company (M/s Jasti Property and Equity Holdings Private Limited) and acquisition of up to 6,61,86,889 equity shares aggregating to 26% of shareholding in the Company from public shareholders through mandatory open offer.
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the Company.
The Acquirer will hold 76.1% of the paid-up share capital of the Company and other foreign investors including FPIs will hold up to 14% of paid-up share capital of the Company subject to compliance with the regulations under various laws and the terms and conditions as specified in the letter of approval.
Read also: Foreign investment of up to Rs 9589 crore in Suven Pharma approved by Cabinet
Medical Dialogues team had earlier reported that Anti-trust regulator Competition Commission of India (CCI) had approved the acquisition of up to 76.10% of the voting share capital of Suven Pharmaceuticals Limited by Berhyanda Limited.
Read also: CCI approves acquisition of up to 76.10 percent of voting share capital of Suven Pharma by Berhyanda
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.